Brief: Santhera Completes Reveragen's Extension Study With Vamorolone In Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG

02/06/2020 06:03

June 2 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG
 SANN.S :
    * SANTHERA ANNOUNCES COMPLETION OF REVERAGEN’S LONG-TERM
EXTENSION
STUDY WITH VAMOROLONE IN DUCHENNE MUSCULAR DYSTROPHY
    * REVERAGEN HAS NOW OBTAINED SAFETY AND EFFICACY DATA WITH
VAMOROLONE OVER A PERIOD OF 2.5 YEARS IN 41 BOYS WITH DMD
    * VAMOROLONE WAS REPORTED TO BE SAFE AND WELL TOLERATED UP
TO
HIGHEST DOSE TESTED

Source text for Eikon:  ID:nGNE7WGyzh 
Further company coverage:  SANN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))